Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Dendritic Cells Subsets Profiles in Classical Hodgkin Lymphoma at Diagnosis and upon Treatment Completion: Analysis on 54 Patients

Domenico Galati, MD PhD, Serena Zanotta, ScD, Gaetano Corazzelli, MD, Bruzzese Dario, PhD, Gaetana Capobianco, MD, Emanuela Morelli, MD, Manuela Arcamone, MD, Ferdinando Frigeri, MD, Rosaria De Filippi, MD PhD, Antonio Pinto, MD

Blood (2017) 130 (Supplement 1): 4095.

https://doi.org/10.1182/blood.V130.Suppl_1.4095.4095

Published: 2017

Journal Articles

Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study

Antonello Pinto, MD, Vincenzo Pavone, MD, Francesco Angrilli, MD, Mariangela Saggese, PharmD, Stefania Crisci, ScD, Caterina Patti, MD, Pier Luigi Zinzani, MD PhD, Alfonso Maria D'Arco, MD, Elena Cavalieri, MD, Attilio Guarini, MD, Michele Spina, MD, Daniela Carlino, MD, Simona Falorio, MD, Emanuela Morelli, MD, Manuela Arcamone, MD, Ferdinando Frigeri, MD PhD, Annarosaria De Chiara, MD, Rosaria De Filippi, MD PhD, Gaetano Corazzelli, MD

Blood (2015) 126 (23): 1541.

https://doi.org/10.1182/blood.V126.23.1541.1541

Published: 2015

Journal Articles

The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones

Rosaria De Filippi, MD PhD, Stefania Crisci, ScD, Michele Cillo, ScD, Sara Mele, BS, Angela De Monaco, ScD, Domenico Galati, MD, Serena Zanotta, ScD, Gaetana Capobianco, MD, Francesco Volzone, MD, Manuela Arcamone, MD, Piera Maiolino, PharmD, Mariangela Saggese, PharmD, Gaetano Corazzelli, MD, Ferdinando Frigeri, MD PhD, Thomas Mehrling, MD PhD, Antonello Pinto, MD

Blood (2015) 126 (23): 2481.

https://doi.org/10.1182/blood.V126.23.2481.2481

Published: 2015

Journal Articles

Molecular Determinants of Bendamustine (BDM) Toxicity towards Hodgkin (H) and Reed-Sternberg (RS) Cell Lines From Hodgkin Lymphoma (HL).

Rosaria De Filippi, MD, PhD, Stefania Crisci, PhD, Ferdinando Frigeri, MD, PhD, Donatella Aldinucci, PhD, Domenico Galati, MD, Rosa Calemma, PhD, Giulio Abagnale, PhD, Gaetana Capobianco, MD, Manuela Arcamone, MD, Raffaele Di Francia, DPharm, Laura Mettivier, MD, Mariangela Saggese, PhD, Gaetano Corazzelli, MD, Antonio Pinto, MD

Blood (2012) 120 (21): 2763.

https://doi.org/10.1182/blood.V120.21.2763.2763

Published: 2012

Journal Articles

90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma. First Results from an International Phase II Clinical Trial

Christian W. Scholz, MD, Antonello Pinto, MD, Werner Linkesch, MD, Ola Linden, MD, Andreas Viardot, MD, Ulrich Keller, MD, Georg Hess, MD, Kristina Lerch, MD, Ferdinando Frigeri, MD, Manuela Arcamone, MD, Bernd Frericks, MD, Christiane Pott, MD, Antonio Pezzutto

Blood (2010) 116 (21): 593.

https://doi.org/10.1182/blood.V116.21.593.593

Published: 2010

Journal Articles

Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial.

Gaetano Corazzelli, MD, Ferdinando Frigeri, MD, Gianpaolo Marcacci, MD, Cristina Becchimanzi, MD, Gaetana Capobianco, MD, Manuela Arcamone, MD, Emanuela Morelli, MD, Francesco Volzone, MD, Filippo Russo, MD, Antonio Pinto, MD

Blood (2010) 116 (21): 2829.

https://doi.org/10.1182/blood.V116.21.2829.2829

Published: 2010

Journal Articles

Biweekly Rituximab, Cyclophosphamide, Vincristine, Non-Pegylated Liposome-Encapsulated Doxorubicin (Myocet®) and Prednisone (R-COMP-14) as Induction Treatment in Poor R-IPI Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) and Pre-Existing Heart Disease.

Ferdinando Frigeri, MD, Gaetano Corazzelli, MD, Manuela Arcamone, MD, Gaetana Capobianco, MD, Anna Lucania, MD, Cristina Becchimanzi, MD, Gianpaolo Marcacci, MD, Filippo Russo, MD, Maria Rosaria Villa, MD, Lucia Mastrullo, MD, Antonio Pinto, MD

Blood (2009) 114 (22): 1664.

https://doi.org/10.1182/blood.V114.22.1664.1664

Published: 2009

Journal Articles

Abnormally Elevated Levels of Serum Free-Immunoglobulin Light Chains Are Frequently Found in Classic Hodgkin Lymphoma (cHL) and Predict Outcome of Patients with Early Stage Disease.

Rosaria De Filippi, MD, PhD, Filippo Russo, MD, Giancarla Iaccarino, D.Sci, Stefania Crisci, D.Sci, Ferdinando Frigeri, Costantino Riemma, Alessandro Marchei, D.Sci, Rosa Calemma, D.Sci, Raffaele Di Francia, D.Pharm, Gianpaolo Marcacci, MD, Gaetano Corazzelli, MD, Gaetana Capobianco, MD, Cristina Becchimanzi, MD, Manuela Arcamone, MD, Barbara Amoroso, MD, Giuseppe Castello, MD, Antonio Pinto, MD

Blood (2009) 114 (22): 267.

https://doi.org/10.1182/blood.V114.22.267.267

Published: 2009

Journal Articles

Safety and Efficacy of Intrathecal Liposome-Encapsulated Cytarabine for Central Nervous System (CNS) Prophylaxis in Adult Patients with Burkitt and Atypical Burkitt Lymphoma Treated with the R-CODOX-M/R-IVAC (Magrath) Regimen: Results of a Phase II Study.

Ferdinando Frigeri, MD, Filippo Russo, MD, Manuela Arcamone, MD, Chiara Fraira, MD, Gennaro Russo, MD, Gaetana Capobianco, MD, Cristina Becchimanzi, MD, Arturo Cuomo, MD, Gianpaolo Marcacci, MD, Gennaro Esposito, MD, Rosaria De Filippi, MD, PhD, Gaetano Corazzelli, MD, Umberto Vitolo, MD, Antonio Pinto, MD

Blood (2009) 114 (22): 3716.

https://doi.org/10.1182/blood.V114.22.3716.3716

Published: 2009

Journal Articles

Dose-Dense(dd) ABVD and Dose-Dense/Dose-Intense(dd-di) ABVD in Newly Diagnosed Patients (pts), Intermediate- and Advanced-Stage with Classical Hodgkin's Lymphoma (cHL): Final Results.

Filippo Russo, MD, Gaetano Corazzelli, MD, Secondo Lastoria, MD, Gianpaolo Marcacci, MD, Ferdinando Frigeri, MD, Gaetana Capobianco, Cristina Becchimanzi, MD, Manuela Arcamone, MD, Antonio Pinto, MD

Blood (2009) 114 (22): 715.

https://doi.org/10.1182/blood.V114.22.715.715

Published: 2009

NARROW

Dendritic Cells Subsets Profiles in Classical Hodgkin Lymphoma at Diagnosis and upon Treatment Completion: Analysis on 54 Patients

Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study

The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones

Molecular Determinants of Bendamustine (BDM) Toxicity towards Hodgkin (H) and Reed-Sternberg (RS) Cell Lines From Hodgkin Lymphoma (HL).

90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma. First Results from an International Phase II Clinical Trial

Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial.

Biweekly Rituximab, Cyclophosphamide, Vincristine, Non-Pegylated Liposome-Encapsulated Doxorubicin (Myocet®) and Prednisone (R-COMP-14) as Induction Treatment in Poor R-IPI Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) and Pre-Existing Heart Disease.

Abnormally Elevated Levels of Serum Free-Immunoglobulin Light Chains Are Frequently Found in Classic Hodgkin Lymphoma (cHL) and Predict Outcome of Patients with Early Stage Disease.

Safety and Efficacy of Intrathecal Liposome-Encapsulated Cytarabine for Central Nervous System (CNS) Prophylaxis in Adult Patients with Burkitt and Atypical Burkitt Lymphoma Treated with the R-CODOX-M/R-IVAC (Magrath) Regimen: Results of a Phase II Study.

Dose-Dense(dd) ABVD and Dose-Dense/Dose-Intense(dd-di) ABVD in Newly Diagnosed Patients (pts), Intermediate- and Advanced-Stage with Classical Hodgkin's Lymphoma (cHL): Final Results.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only